Emerging pathways for precision medicine in management of cholangiocarcinoma.
Aberrant signaling pathway
Cholangiocarcinoma
Targeted Therapy
Journal
Surgical oncology
ISSN: 1879-3320
Titre abrégé: Surg Oncol
Pays: Netherlands
ID NLM: 9208188
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
received:
31
05
2020
accepted:
06
08
2020
pubmed:
23
8
2020
medline:
9
10
2021
entrez:
23
8
2020
Statut:
ppublish
Résumé
Cholangiocarcinoma (CCA) is the second most common biliary tract malignancy with a dismal prognosis. Surgical resection with a negative microscopic margin offers the only hope for long-term survival. However, the majority of patients present with advanced disease not amenable to curative resection, mainly due to late presentation and aggressive nature of the disease. Unfortunately, due to the heterogeneous nature of CCA as well as limitations of available chemotherapy medications, traditional chemotherapy regimens offer limited survival benefit. Recent advances in genomic studies and next-generation sequencing techniques have assisted in better understanding of cholangiocarcinogenesis and identification of potential aberrant signaling pathways. Targeting the specific genomic abnormalities via novel molecular therapies has opened a new avenue in management of CCA with encouraging results in preclinical studies and early clinical trials. In this review, we present emerging therapies for precision medicine in CCA.
Identifiants
pubmed: 32827952
pii: S0960-7404(20)30352-2
doi: 10.1016/j.suronc.2020.08.008
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
47-55Informations de copyright
Copyright © 2020 Elsevier Ltd. All rights reserved.